Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
RIGL's Cash to Debt is ranked higher than
93% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. RIGL: No Debt )
RIGL' s 10-Year Cash to Debt Range
Min: 4.48   Max: No Debt
Current: No Debt

Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
99% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. RIGL: No Debt )
RIGL' s 10-Year Interest Coverage Range
Min: 388.1   Max: 9999.99
Current: No Debt

388.1
9999.99
F-Score: 4
Z-Score: -0.62
M-Score: -0.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1492.61
RIGL's Operating margin (%) is ranked lower than
54% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. RIGL: -1492.61 )
RIGL' s 10-Year Operating margin (%) Range
Min: -14938.27   Max: 28.25
Current: -1492.61

-14938.27
28.25
Net-margin (%) -1486.90
RIGL's Net-margin (%) is ranked lower than
54% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. RIGL: -1486.90 )
RIGL' s 10-Year Net-margin (%) Range
Min: -14872.93   Max: 30.31
Current: -1486.9

-14872.93
30.31
ROE (%) -45.84
RIGL's ROE (%) is ranked higher than
52% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. RIGL: -45.84 )
RIGL' s 10-Year ROE (%) Range
Min: -142.04   Max: 27.46
Current: -45.84

-142.04
27.46
ROA (%) -42.14
RIGL's ROA (%) is ranked higher than
51% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. RIGL: -42.14 )
RIGL' s 10-Year ROA (%) Range
Min: -101.94   Max: 23.14
Current: -42.14

-101.94
23.14
ROC (Joel Greenblatt) (%) -2182.40
RIGL's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. RIGL: -2182.40 )
RIGL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4462.67   Max: 1034.93
Current: -2182.4

-4462.67
1034.93
Revenue Growth (3Y)(%) -67.70
RIGL's Revenue Growth (3Y)(%) is ranked lower than
52% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. RIGL: -67.70 )
RIGL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 75.5
Current: -67.7

0
75.5
» RIGL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

RIGL Guru Trades in Q4 2013

Jim Simons 1,150,139 sh (+152.59%)
Steven Cohen 21,600 sh (+63.64%)
Chuck Royce 308,992 sh (+25.61%)
» More
Q1 2014

RIGL Guru Trades in Q1 2014

Paul Tudor Jones 11,687 sh (New)
Charles Brandes 15,000 sh (New)
Steven Cohen 27,339 sh (+26.57%)
Chuck Royce 309,392 sh (+0.13%)
Jim Simons 210,526 sh (-81.7%)
» More
Q2 2014

RIGL Guru Trades in Q2 2014

Jim Simons 421,254 sh (+100.1%)
Paul Tudor Jones 11,950 sh (+2.25%)
Charles Brandes 15,000 sh (unchged)
Chuck Royce 215,392 sh (-30.38%)
» More
Q3 2014

RIGL Guru Trades in Q3 2014

Jim Simons 589,326 sh (+39.9%)
Chuck Royce 215,392 sh (unchged)
Charles Brandes Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-09-30 Sold Out $1.97 - $3.84 $ 2.44-13%0
Charles Brandes 2014-03-31 New Buy$2.7 - $4.75 $ 2.44-31%15000
George Soros 2011-12-31 Sold Out 0.0019%$6.68 - $8.3 $ 2.44-68%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.46
RIGL's P/B is ranked higher than
89% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. RIGL: 1.46 )
RIGL' s 10-Year P/B Range
Min: 1.02   Max: 15.5
Current: 1.46

1.02
15.5
P/S 34.86
RIGL's P/S is ranked higher than
54% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. RIGL: 34.86 )
RIGL' s 10-Year P/S Range
Min: 2.8   Max: 979
Current: 34.86

2.8
979
Current Ratio 15.58
RIGL's Current Ratio is ranked higher than
97% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. RIGL: 15.58 )
RIGL' s 10-Year Current Ratio Range
Min: 1.84   Max: 36.3
Current: 15.58

1.84
36.3
Quick Ratio 15.58
RIGL's Quick Ratio is ranked higher than
97% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. RIGL: 15.58 )
RIGL' s 10-Year Quick Ratio Range
Min: 1.84   Max: 36.3
Current: 15.58

1.84
36.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.51
RIGL's Price/Net Cash is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. RIGL: 1.51 )
RIGL' s 10-Year Price/Net Cash Range
Min: 1.2   Max: 18.79
Current: 1.51

1.2
18.79
Price/Net Current Asset Value 1.51
RIGL's Price/Net Current Asset Value is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. RIGL: 1.51 )
RIGL' s 10-Year Price/Net Current Asset Value Range
Min: 1.2   Max: 18.11
Current: 1.51

1.2
18.11
Price/Tangible Book 1.46
RIGL's Price/Tangible Book is ranked higher than
91% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. RIGL: 1.46 )
RIGL' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 14.13
Current: 1.46

1.02
14.13
Price/Median PS Value 0.93
RIGL's Price/Median PS Value is ranked higher than
85% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. RIGL: 0.93 )
RIGL' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 25.7
Current: 0.93

0.04
25.7
Earnings Yield (Greenblatt) -151.50
RIGL's Earnings Yield (Greenblatt) is ranked lower than
56% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. RIGL: -151.50 )
RIGL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 10.5   Max: 6128.3
Current: -151.5

10.5
6128.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:RI2A.Germany,
Rigel Pharmaceuticals Inc was incorporated in the state of Delaware on June 14, 1996. The Company is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Companys pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor entering in Phase 3 clinical trials for immune thrombocytopenic purpura (ITP) and a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator entering Phase 1 in the first half of 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo, respectively. The Company is conducting proprietary research in the broad disease areas of inflammation/immunology and muscle wasting/muscle endurance. The Companys major competitors include fully integrated pharmaceutical companies that have extensive drug discovery efforts and are developing novel small molecule pharmaceuticals. The Company is subject to extensive regulation by numerous governmental authorities in the United States and other countries, including the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for RIGL

Headlines

Articles On GuruFocus.com
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Nov 24 2014
Rigel Announces Executive Management Changes Nov 24 2014
Rigel Announces Executive Management Changes Nov 24 2014
RIGEL PHARMACEUTICALS INC Financials Nov 14 2014
10-Q for Rigel Pharmaceuticals, Inc. Nov 06 2014
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 04 2014
RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 04 2014
Rigel posts 3Q loss Nov 04 2014
Rigel posts 3Q loss Nov 04 2014
Rigel Announces Third Quarter 2014 Financial Results Nov 04 2014
Rigel Announces Third Quarter 2014 Financial Results Nov 04 2014
Rigel's R348 Fails in Phase II Study, Shares Down 13.6% Aug 14 2014
Why Rigel Pharmaceuticals (RIGL) Stock Is Declining Today Aug 13 2014
Rigel eye drug fails mid-stage study, shares fall Aug 13 2014
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 13 2014
Rigel experimental eye drug fails mid-stage study Aug 13 2014
R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study Aug 13 2014
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2014
RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2014
Rigel Announces Second Quarter 2014 Financial Results Aug 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK